IMB Dx (KOSDAQ:A461030) - Stock Price, News & Analysis

A461030 Stock Overview

Provides liquid biopsy platform in South Korea.

A461030 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months

IMB Dx, Inc. Competitors

AbClon

KOSDAQ:A174900

₩253.2b

Amicogen

KOSDAQ:A092040

₩253.8b

ISU Abxis

KOSDAQ:A086890

₩226.9b

Genexine

KOSDAQ:A095700

₩261.1b

Price History & Performance

Summary of all time highs, changes and price drops for IMB Dx
Historical stock prices
Current Share Price	₩17,150.00
52 Week High	₩40,550.00
52 Week Low	₩8,430.00
Beta	0
11 Month Change	-20.05%
3 Month Change	60.43%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-52.36%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	A461030	KR Biotechs	KR Market
7D	-11.9%	-4.2%	2.4%
1Y	n/a	40.6%	5.0%

Return vs Industry: Insufficient data to determine how A461030 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A461030 performed against the KR Market.

Price Volatility

Is A461030's price volatile compared to industry and market?
A461030 volatility
A461030 Average Weekly Movement	16.5%
Biotechs Industry Average Movement	9.4%
Market Average Movement	6.7%
10% most volatile stocks in KR Market	12.0%
10% least volatile stocks in KR Market	3.5%

Stable Share Price: A461030's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine A461030's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	n/a	www.imbdx.com

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection.

IMB Dx, Inc. Fundamentals Summary

How do IMB Dx's earnings and revenue compare to its market cap?
A461030 fundamental statistics
Market cap	₩240.40b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A461030 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A461030 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A461030 perform over the long term?

See historical performance and comparison